FDA Advisers Recommend J&J Vaccine Receive Emergency Use Authorization
On Friday, a panel of vaccine advisers to the FDA recommended that the agency grant emergency use authorization for the Johnson & Johnson Covid-19 vaccine.
The FDA's Vaccine and Related Biological Products Advisory Committee voted unanimously in favor of approving the J&J vaccine for emergency use in people 18 or older.
The FDA is expected to act on the recommendation quickly. If approved, the Johnson and Johnson vaccine would become the third Covid-19 vaccine in the US to receive emergency use authorization, along with Pfizer and Moderna. The J&J vaccine would also become the first single-dose vaccine authorized to treat the virus.
The Johnson & Johnson vaccine was found to be 66.9% effective at preventing moderate to severe Covid-19 symptoms and 85% effective against very serious symptoms. The J&J vaccine was less effective against the mutated South African version of the virus.
J&J says they can roll-out 100 million doses by the end of June, if they receive FDA approval.
Although less effective than the two-dose Pfizer and Moderna vaccines, J&J's single-dose vaccine could be much easier to roll-out and does not require the same sub-zero refrigeration, facilitating transportation and storage.
Photo Source: Angelo Esslinger